These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 17721546)

  • 1. Broad HIV-1 neutralization mediated by CD4-binding site antibodies.
    Li Y; Migueles SA; Welcher B; Svehla K; Phogat A; Louder MK; Wu X; Shaw GM; Connors M; Wyatt RT; Mascola JR
    Nat Med; 2007 Sep; 13(9):1032-4. PubMed ID: 17721546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A potent, neutralizing human monoclonal antibody against a unique epitope overlapping the CD4-binding site of HIV-1 gp120 that is broadly conserved across North American and African virus isolates.
    Pinter A; Honnen WJ; Racho ME; Tilley SA
    AIDS Res Hum Retroviruses; 1993 Oct; 9(10):985-96. PubMed ID: 7506556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes.
    Moulard M; Phogat SK; Shu Y; Labrijn AF; Xiao X; Binley JM; Zhang MY; Sidorov IA; Broder CC; Robinson J; Parren PW; Burton DR; Dimitrov DS
    Proc Natl Acad Sci U S A; 2002 May; 99(10):6913-8. PubMed ID: 11997472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymphocytotropic strains of HIV type 1 when complexed with enhancing antibodies can infect macrophages via Fc gamma RIII, independently of CD4.
    Trischmann H; Davis D; Lachmann PJ
    AIDS Res Hum Retroviruses; 1995 Mar; 11(3):343-52. PubMed ID: 7540399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network.
    Montefiori DC; Graham BS; Zhou J; Zhou J; Bucco RA; Schwartz DH; Cavacini LA; Posner MR
    J Clin Invest; 1993 Aug; 92(2):840-7. PubMed ID: 8349820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural mimicry of CD4 by a cross-reactive HIV-1 neutralizing antibody with CDR-H2 and H3 containing unique motifs.
    Prabakaran P; Gan J; Wu YQ; Zhang MY; Dimitrov DS; Ji X
    J Mol Biol; 2006 Mar; 357(1):82-99. PubMed ID: 16426633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors.
    Dhillon AK; Donners H; Pantophlet R; Johnson WE; Decker JM; Shaw GM; Lee FH; Richman DD; Doms RW; Vanham G; Burton DR
    J Virol; 2007 Jun; 81(12):6548-62. PubMed ID: 17409160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
    Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
    Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Peptides from the principal neutralizing and CD4-binding domain: similar immunoreactive properties and structure pattern].
    Meshcheriakova DV; Andreev SM; Sidorova MV; Vafina MG; Az'muko AA; Petrukhina AO; Khaitov RM
    Vestn Ross Akad Med Nauk; 1992; (9-10):47-52. PubMed ID: 1283721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
    Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR
    J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-Leu3a induces combining site-related anti-idiotypic antibody without inducing anti-HIV activity.
    Reeves JP; Buck D; Berkower I; Murphy D; Epstein SL
    AIDS Res Hum Retroviruses; 1991 Jan; 7(1):55-63. PubMed ID: 2015115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 (HXB2-Env:Ala 582(-->Thr)) decreases viral neutralization by monoclonal antibodies to the CD4-binding site.
    Klasse PJ; McKeating JA; Schutten M; Reitz MS; Robert-Guroff M
    Virology; 1993 Sep; 196(1):332-7. PubMed ID: 8356803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased sensitivity to CD4 binding site-directed neutralization following in vitro propagation on primary lymphocytes of a neutralization-resistant human immunodeficiency virus IIIB strain isolated from an accidentally infected laboratory worker.
    Beaumont T; Quakkelaar E; van Nuenen A; Pantophlet R; Schuitemaker H
    J Virol; 2004 Jun; 78(11):5651-7. PubMed ID: 15140962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A CD4-derived peptide carrier blocks acute HIV-1 infection in vitro and binds to gp120 in the presence of Walter-Reed stage 1-6 HIV+ sera.
    Ghetie V; Wheeler T; Scott D; Uhr JW; Vitetta ES
    AIDS Res Hum Retroviruses; 1992 Nov; 8(11):1945-8. PubMed ID: 1489581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of CD4-Binding Site Dependent Plasma Neutralizing Antibodies in an HIV-1 Infected Indian Individual.
    Khan L; Makhdoomi MA; Kumar S; Nair A; Andrabi R; Clark BE; Auyeung K; Bhattacharya J; Vajpayee M; Wig N; Pantophlet R; Luthra K
    PLoS One; 2015; 10(5):e0125575. PubMed ID: 25962059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gp120/CD4 blocking antibodies are frequently elicited in ART-naïve chronically HIV-1 infected individuals.
    Carrillo J; Molinos-Albert LM; Rodríguez de la Concepción ML; Marfil S; García E; Derking R; Sanders RW; Clotet B; Blanco J
    PLoS One; 2015; 10(3):e0120648. PubMed ID: 25803681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B cell recognition of the conserved HIV-1 co-receptor binding site is altered by endogenous primate CD4.
    Forsell MN; Dey B; Mörner A; Svehla K; O'dell S; Högerkorp CM; Voss G; Thorstensson R; Shaw GM; Mascola JR; Karlsson Hedestam GB; Wyatt RT
    PLoS Pathog; 2008 Oct; 4(10):e1000171. PubMed ID: 18833294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a new neutralizing epitope conformationally affected by the attachment of CD4 to gp120.
    Kang CY; Hariharan K; Posner MR; Nara P
    J Immunol; 1993 Jul; 151(1):449-57. PubMed ID: 7686944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants.
    Li Y; Svehla K; Mathy NL; Voss G; Mascola JR; Wyatt R
    J Virol; 2006 Feb; 80(3):1414-26. PubMed ID: 16415019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of CD4-induced epitopes on the HIV type 1 gp120 envelope glycoprotein recognized by neutralizing human monoclonal antibodies.
    Xiang SH; Doka N; Choudhary RK; Sodroski J; Robinson JE
    AIDS Res Hum Retroviruses; 2002 Nov; 18(16):1207-17. PubMed ID: 12487827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.